Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Financing Activities (2020 - 2025)

Apellis Pharmaceuticals has reported Cash from Financing Activities over the past 6 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $1.3 million for Q4 2025, up 131.48% from a year ago — trailing twelve months through Dec 2025 was $8.9 million (down 94.05% YoY), and the annual figure for FY2025 was $8.9 million, down 94.05%.
  • Cash from Financing Activities for Q4 2025 was $1.3 million at Apellis Pharmaceuticals, up from $793000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for APLS hit a ceiling of $391.1 million in Q1 2023 and a floor of -$15.9 million in Q4 2022.
  • Median Cash from Financing Activities over the past 5 years was $2.3 million (2021), compared with a mean of $65.5 million.
  • Peak annual rise in Cash from Financing Activities hit 22982.35% in 2022, while the deepest fall reached 204.62% in 2022.
  • Apellis Pharmaceuticals' Cash from Financing Activities stood at $384.0 million in 2021, then crashed by 104.15% to -$15.9 million in 2022, then skyrocketed by 75.46% to -$3.9 million in 2023, then decreased by 2.22% to -$4.0 million in 2024, then surged by 131.48% to $1.3 million in 2025.
  • The last three reported values for Cash from Financing Activities were $1.3 million (Q4 2025), $793000.0 (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.